Bender Robert & Associates’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $475K | Buy |
+34,701
| New | +$475K | 0.11% | 32 |
|
|
2025
Q1 | – | Sell |
-34,701
| Closed | -$370K | – | 48 |
|
|
2024
Q4 | $370K | Buy |
+34,701
| New | +$370K | 0.09% | 36 |
|
|
2024
Q2 | – | Sell |
-34,701
| Closed | -$521K | – | 42 |
|
|
2024
Q1 | $521K | Hold |
34,701
| – | – | 0.12% | 36 |
|
|
2023
Q4 | $521K | Hold |
34,701
| – | – | 0.13% | 38 |
|
|
2023
Q3 | $486K | Hold |
34,701
| – | – | 0.14% | 38 |
|
|
2023
Q2 | $359K | Hold |
34,701
| – | – | 0.1% | 40 |
|
|
2023
Q1 | $321K | Buy |
+34,701
| New | +$321K | 0.1% | 45 |
|
|
2022
Q4 | – | Sell |
-41,131
| Closed | -$342K | – | 52 |
|
|
2022
Q3 | $342K | Hold |
41,131
| – | – | 0.13% | 43 |
|
|
2022
Q2 | $337K | Buy |
+41,131
| New | +$337K | 0.13% | 42 |
|
|
2021
Q2 | – | Sell |
-31,131
| Closed | -$606K | – | 54 |
|
|
2021
Q1 | $606K | Buy |
+31,131
| New | +$606K | 0.2% | 37 |
|